Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
OPXA's Cash to Debt is ranked higher than
87% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. OPXA: No Debt )
OPXA' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: No Debt

Equity to Asset 0.78
OPXA's Equity to Asset is ranked higher than
81% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OPXA: 0.78 )
OPXA' s 10-Year Equity to Asset Range
Min: -1191   Max: 0.78
Current: 0.78

-1191
0.78
F-Score: 4
Z-Score: -2.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -941.04
OPXA's Operating margin (%) is ranked higher than
54% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. OPXA: -941.04 )
OPXA' s 10-Year Operating margin (%) Range
Min: -2950   Max: -12.65
Current: -941.04

-2950
-12.65
Net-margin (%) -1314.60
OPXA's Net-margin (%) is ranked higher than
52% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. OPXA: -1314.60 )
OPXA' s 10-Year Net-margin (%) Range
Min: -2200   Max: -6.13
Current: -1314.6

-2200
-6.13
ROE (%) -80.94
OPXA's ROE (%) is ranked higher than
57% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. OPXA: -80.94 )
OPXA' s 10-Year ROE (%) Range
Min: -797.04   Max: -19.44
Current: -80.94

-797.04
-19.44
ROA (%) -63.48
OPXA's ROA (%) is ranked higher than
57% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. OPXA: -63.48 )
OPXA' s 10-Year ROA (%) Range
Min: -19900   Max: -15.39
Current: -63.48

-19900
-15.39
ROC (Joel Greenblatt) (%) -920.69
OPXA's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. OPXA: -920.69 )
OPXA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14400   Max: -339.81
Current: -920.69

-14400
-339.81
EBITDA Growth (%) -2.10
OPXA's EBITDA Growth (%) is ranked higher than
80% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. OPXA: -2.10 )
OPXA' s 10-Year EBITDA Growth (%) Range
Min: -67.4   Max: 43.4
Current: -2.1

-67.4
43.4
EPS Growth (%) -0.80
OPXA's EPS Growth (%) is ranked higher than
82% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. OPXA: -0.80 )
OPXA' s 10-Year EPS Growth (%) Range
Min: -64.4   Max: 49.6
Current: -0.8

-64.4
49.6
» OPXA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OPXA



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Opexa Therapeutics, Inc.

Weekly CFO Buys Highlight
According to GuruFocus Insider Data , these are the largest CFO buys during the past week. The overall trend of CFOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/B 1.60
OPXA's P/B is ranked higher than
90% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. OPXA: 1.60 )
OPXA' s 10-Year P/B Range
Min: 1.6   Max: 11
Current: 1.6

1.6
11
P/S 15.70
OPXA's P/S is ranked lower than
56% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. OPXA: 15.70 )
OPXA' s 10-Year P/S Range
Min: 14.6   Max: 78
Current: 15.7

14.6
78
EV-to-EBIT 0.20
OPXA's EV-to-EBIT is ranked higher than
97% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. OPXA: 0.20 )
OPXA' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 0.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.90
OPXA's Price/Net Cash is ranked higher than
93% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. OPXA: 1.90 )
OPXA' s 10-Year Price/Net Cash Range
Min: 2.3   Max: 40.5
Current: 1.9

2.3
40.5
Price/Net Current Asset Value 1.90
OPXA's Price/Net Current Asset Value is ranked higher than
94% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. OPXA: 1.90 )
OPXA' s 10-Year Price/Net Current Asset Value Range
Min: 2.3   Max: 40.5
Current: 1.9

2.3
40.5
Price/Tangible Book 1.70
OPXA's Price/Tangible Book is ranked higher than
91% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. OPXA: 1.70 )
OPXA' s 10-Year Price/Tangible Book Range
Min: 1.58   Max: 7.59
Current: 1.7

1.58
7.59
Price/Median PS Value 0.70
OPXA's Price/Median PS Value is ranked higher than
84% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. OPXA: 0.70 )
OPXA' s 10-Year Price/Median PS Value Range
Min: 0.87   Max: 0.87
Current: 0.7

Forward Rate of Return (Yacktman) -73.44
OPXA's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. OPXA: -73.44 )
OPXA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -73.44

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:P6NN.Germany
Opexa Therapeutics, Inc., formerly known as Pharma was incorporated in Texas in March 1991. It is a biopharmaceutical company developing personalized cellular therapies with the potential to treat major illnesses, including multiple sclerosis (MS). These therapies are based on its proprietary T-cell technology. Information related to its product candidate is preliminary and investigative. Its product candidate, Tcelna, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tcelna is a novel T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with secondary progressive MS (SPMS). It is also positioned to enter Phase III clinical development for the treatment of patients with relapsing remitting MS (RRMS), subject to the availability of sufficient resources. In September 2012, the company announced the initiation of a Phase IIb clinical trial of Tcelna in patients with SPMS. SPMS is characterized by a steady accrual of irreversible disability, despite, in some cases, reversible relapses, remissions or clinical plateaus. Older age at onset of MS diagnosis is the strongest predictor of conversion to SPMS. Males have a shorter time to conversion to SPMS compared with females. Its proprietary T-cell technology has enabled to develop intellectual property and a comprehensive sample database that may enable discovery of novel biomarkers and other relevant peptides to be used to treat MS patients. The Company has developed a proprietary adult stem cell technology to produce monocyte-derived stem cells (MDSC) from blood. These MDSC can be derived from a patient's monocytes, expanded ex vivo, and then administered to the same patient. The Company manufactures its TCV therapy in its own Good Manufacturing Practice `GMP' facility. The TCV technology used to produce Tovaxin is similar to that of traditional microbial vaccine technology, where the pathogen 'or the attenuated derivative' is used to derive the protective antigens necessary to induce protective immune responses. Its research and development activities and the future manufacturing and marketing of its potential products are, and would be, subject to regulation for safety and efficacy by a number of governmental authorities in the United States and other countries. Major pharmaceutical Companies currently offer a number of pharmaceutical products to treat MS, heart attack, stroke, Parkinson's disease, diabetes, liver diseases, arthritis and other diseases for which the company's technologies might be applicable. In the U.S., pharmaceuticals, biologicals and medical devices are subject to FDA regulation.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide